Neornat Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$2.67M
- Investors
-
9
Neornat General Information
Description
Developer of neo-RNA therapeutics designed to offer anticancer drugs. The company uses data-based liver cancer diagnosis technology for macrophage immuno-oncology and RNA regulator-targeted anticancer with sensitivity and specificity, enabling medical professionals to offer patients effective treatment by early detection of liver cancer.
Contact Information
Website
neornat.comCorporate Office
- 47-3 Banpo-daero 39-gil
- Seocho-gu, Seowoo Building, 2nd floor
- Seoul, 06591
- South Korea
Corporate Office
- 47-3 Banpo-daero 39-gil
- Seocho-gu, Seowoo Building, 2nd floor
- Seoul, 06591
- South Korea
Neornat Timeline
Neornat Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Early Stage VC | 01-Dec-2023 | $2.67M | Completed | Generating Revenue | ||
| 6. Accelerator/Incubator | 01-May-2023 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 01-May-2023 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Nov-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 28-Mar-2022 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 30-Apr-2021 | $446K | $446K | Completed | Generating Revenue | |
| 1. Seed Round | 17-Mar-2021 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Neornat Patents
Neornat Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210254174-A1 | Liver cancer-specific biomarker | Inactive | 14-Jun-2018 |
Neornat Signals
Neornat Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Korea Technology Finance | Government | Minority | ||
| DB Financial Investment | Asset Manager | Minority | ||
| DTR Partners | Venture Capital | Minority | ||
| GeneN Investment Partners | Venture Capital | Minority | ||
| Tech Incubator Program for Startup | Accelerator/Incubator |
Neornat FAQs
-
When was Neornat founded?
Neornat was founded in 2020.
-
Where is Neornat headquartered?
Neornat is headquartered in Seoul, South Korea.
-
What is the size of Neornat?
Neornat has 6 total employees.
-
What industry is Neornat in?
Neornat’s primary industry is Drug Discovery.
-
Is Neornat a private or public company?
Neornat is a Private company.
-
What is Neornat’s current revenue?
The current revenue for Neornat is .
-
How much funding has Neornat raised over time?
Neornat has raised $3.19M.
-
Who are Neornat’s investors?
Korea Technology Finance, DB Financial Investment, DTR Partners, GeneN Investment Partners, and Tech Incubator Program for Startup are 5 of 9 investors who have invested in Neornat.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process